In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factorα mediated killing of c-Ha-ras-transformed cells
- 1 November 1992
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 35 (6) , 388-394
- https://doi.org/10.1007/bf01789017
Abstract
Cellular subclones of high and low tumorigenicity obtained from a mouse c-Ha-ras-transformed clone, were examined for their sensitivity to tumornecrosis-factor (TNF)-mediated cytotoxicity. Cells of the highly tumorigenic subclones showed a significantly enhanced resistance to the cytotoxic effect of TNF plus cyclohexamide (CHI) as compared to cells of the lowtumorigenic subclones. The enhanced resistance to TNF+CHI was not due to a lower expression of TNF receptors on the cells. The c-Ha-ras-transfected cells were transformed and maintained in culture only (C cells). In vivo passage of cells of the initially low-tumorigenic c-Ha-ras subclones through the mouse significantly enhanced the tumorigenic potential of these CTC cells (culture/tumor/culture). In correlation with their enhanced tumorigenicity, the CTC cells were highly resistant to TNF-mediated cytotoxicity as compared to C cells of the same subclone. Furthermore, the involvement of TNF in determining the tumorigenic phenotype of the c-Ha-ras-transformed cells was demonstrated in a more direct manner. Cells of a c-Ha-ras-transformed low-tumorigenic, highly TNF-sensitive subclone were selected by repeated cycles of in vitro exposure to TNFα. As a result, a stable, highly TNF-resistant population of cells emerged. These TNF-resistant cells caused more tumors in mice as compared to their original TNF-sensitive cells. These results show that the resistance to the cytotoxic effect of TNF plus cyclohexamide may be involved, at least partially, in the tumorigenic potential of c-Ha-ras-transformed cells and suggest a possible role for TNF in the enhancement of the tumorigenic potential of these cells in mice.Keywords
This publication has 36 references indexed in Scilit:
- Tumour cells which develop resistance to cytolysis by tumour necrosis factor have a different glycoform of a 105‐kda glycoprotein and lose the capacity to invade and metastasizeInternational Journal of Cancer, 1990
- Tumour necrosis factor as an anticancer agentEuropean Journal of Cancer and Clinical Oncology, 1990
- Tumors secreting human TNF/cachectin induce cachexia in miceCell, 1987
- Tumor Necrosis Factor (TNF)Science, 1985
- Translocation, breakage and truncated transcripts of c-myc oncogene in murine plasmacytomasNature, 1983
- Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogeneNature, 1983
- Number and evolutionary conservation of α- and β-tubulin and cytoplasmic β- and γ-actin genes using specific cloned cDNA probesCell, 1980
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978